<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1662">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523181</url>
  </required_header>
  <id_info>
    <org_study_id>GHCovid-2-001</org_study_id>
    <nct_id>NCT04523181</nct_id>
  </id_info>
  <brief_title>Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients</brief_title>
  <official_title>A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Golden Biotechnology Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Golden Biotechnology Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety andefficacy of antroquinonol treatment of mild to moderate pneumonia&#xD;
      due to COVID-19, as measured by the proportion of patients alive and free of respiratory&#xD;
      failure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double blind, placebo controlled, Phase 2, proof of concept study in&#xD;
      hospitalized patients with mild to moderate pneumonia due to COVID 19. Written informed&#xD;
      consent must be obtained from all patients during screening. Following completion of all&#xD;
      screening assessments and meeting of eligibility criteria, patients will either receive&#xD;
      antroquinonol or placebo for 14 days in combination with SoC therapy per local SoC policies.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Anticipated">May 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A Phase 2 Randomized, Double blind, Placebo Controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients with Mild to Moderate Pneumonia due to COVID 19</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double blind, Placebo Controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>recover ratio</measure>
    <time_frame>14 day</time_frame>
    <description>The proportion of patients who are alive and free of respiratory failure (e.g., no need for invasive mechanical ventilation, non invasive ventilation, high flow oxygen, or ECMO) on Day 14</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to 2-point improvement</measure>
    <time_frame>28 day</time_frame>
    <description>Clinical change score as measured by the WHO COVID-19 Clinical Improvement Ordinal Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of hospitalization</measure>
    <time_frame>28 day</time_frame>
    <description>time for patient discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virological clearance</measure>
    <time_frame>28 day</time_frame>
    <description>measured as study days from start of treatment to first negative SARS CoV 2 PCR test</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">174</enrollment>
  <condition>Covid-19</condition>
  <arm_group>
    <arm_group_label>Antroquinonol with SOC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Antroquinonol in a dose of 100 mg (1 capsule) administered twice daily (BID) orally, for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo with SOC</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo (1 capsule) administered twice daily (BID) orally, for 14 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antroquinonol</intervention_name>
    <description>double-blind for antroquinonol and Placebo with same out-look and same frequency.</description>
    <arm_group_label>Antroquinonol with SOC</arm_group_label>
    <other_name>Hocena</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Capsule without active compound</description>
    <arm_group_label>Placebo with SOC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Willing and able to provide informed consent.&#xD;
&#xD;
          2. Male or female patients between 18 and 80 years of age.&#xD;
&#xD;
          3. Hospitalized with COVID 19 disease (not requiring oxygen therapy [WHO COVID-19&#xD;
             Clinical Improvement Ordinal Scale, score of 3] or requiring oxygen therapy by mask or&#xD;
             nasal prong [WHO COVID-19 Clinical Improvement Ordinal Scale, score of 4]).&#xD;
&#xD;
             Note: Hospitalized patients can also include patients admitted to centers conditioned&#xD;
             as hospitals to treat COVID-19 patients.&#xD;
&#xD;
          4. Chest x ray or computerized tomography (CT) scan consistent with mild to moderate&#xD;
             pneumonia.&#xD;
&#xD;
          5. Onset of COVID-19 symptoms within 5 days prior to screening.&#xD;
&#xD;
          6. SARS CoV 2 infection confirmed by a polymerase chain reaction (PCR) test&#xD;
             (nasopharyngeal, oropharyngeal, or respiratory samples, not serology testing).&#xD;
&#xD;
          7. Male patients and female patients of childbearing potential must agree to use&#xD;
             protocol-specified methods of contraception.&#xD;
&#xD;
          8. Females patients of childbearing potential must have a negative pregnancy test at&#xD;
             Screening or pretreatment on Day 1.&#xD;
&#xD;
          9. Male patients must agree not to donate sperm from the first dose through 90 days after&#xD;
             the last dose of study treatment; female patients of childbearing potential should&#xD;
             refrain from donation of ova from Day 1 until 90 days after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
         10. Patient is, in the opinion of the investigator, willing and able to comply with the&#xD;
             study treatment regimen and all other study requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female patient is pregnant or breastfeeding.&#xD;
&#xD;
          2. Any patient's concomitant life threatening condition, including but not limited to:&#xD;
             requiring mechanical ventilation, acute respiratory distress syndrome, shock, or&#xD;
             cardiac failure.&#xD;
&#xD;
          3. Evidence of lobar or sublobar consolidation on chest x ray.&#xD;
&#xD;
          4. Severe COVID 19 disease as defined by the WHO COVID-19 Clinical Improvement Ordinal&#xD;
             Scale, scores of 5 (non invasive ventilation or high flow oxygen), 6 (intubation and&#xD;
             mechanical ventilation), or 7 (ventilation + additional organ support pressors, renal&#xD;
             replacement therapy [RRT], ECMO).&#xD;
&#xD;
          5. Medical history significant for the following pulmonary diseases: lung cancer, cystic&#xD;
             fibrosis, empyema.&#xD;
&#xD;
          6. Peripheral capillary oxygen saturation (SpO2) &lt;90% in room air.&#xD;
&#xD;
          7. History of buse of drugs or alcohol that could interfere with adherence to study&#xD;
             requirements, as judged by the investigator.&#xD;
&#xD;
          8. Treatment with other drugs thought to possibly have activity against COVID 19 within 7&#xD;
             days prior to enrollment or concurrently. Note: remdesivir is allowed if considered&#xD;
             SoC, if started prior to randomization.&#xD;
&#xD;
          9. Use of other investigational drugs within 30 days of dosing, or plans to enroll in&#xD;
             another clinical trial of an investigational agent while participating in the present&#xD;
             study.&#xD;
&#xD;
         10. Use of Antrodia camphorata -containing products within 2 weeks prior to the first&#xD;
             administration of study drug.&#xD;
&#xD;
         11. Clinically significant abnormal electrocardiogram (ECG) at Screening, as determined by&#xD;
             the investigator.&#xD;
&#xD;
         12. Patient requires frequent or prolonged use of systemic corticosteroids (≥20 mg of&#xD;
             prednisone/day or equivalent for &gt;4 weeks) or other immunosuppressive drugs (e.g., for&#xD;
             organ transplantation or autoimmune conditions).&#xD;
&#xD;
         13. Abnormal laboratory values at Screening:&#xD;
&#xD;
               1. Estimated glomerular filtration rate &lt;50 mL/min.&#xD;
&#xD;
               2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;5 × upper&#xD;
                  limit of normal (ULN), or ALT/AST &gt;3 × ULN plus total bilirubin &gt;2 × ULN.&#xD;
&#xD;
               3. Total bilirubin &gt;1.5 × ULN, unless the patient has known Gilbert's syndrome.&#xD;
&#xD;
               4. Hemoglobin &lt;9 g/dL for females or &lt;11 g/dL for males.&#xD;
&#xD;
               5. Absolute neutrophil count &lt;1,500/mm3.&#xD;
&#xD;
               6. Thrombocytopenia (platelets count &lt;100 × 109/L).&#xD;
&#xD;
         14. Treatment with any antiviral drugs (except remdesivir), or with any drugs known to be&#xD;
             strong inducers or inhibitors of cytochrome P450 isoform (CYP) 2C19, CYP3A4, CYP2C8&#xD;
             and CYP2E1 within 14 days or 5 half lives prior to the start of study treatment. Drugs&#xD;
             with a narrow therapeutic index that are substrates of 1A2, 2B6, 2C8, 2C9, 2C19, 3A,&#xD;
             and 2D6 are also prohibited&#xD;
&#xD;
         15. Inability to swallow oral medications or a gastrointestinal disorder with diarrhea&#xD;
             (e.g., Crohn's disease), malabsorption, or diarrhea of any etiology at baseline.&#xD;
&#xD;
         16. Any other clinically significant medical condition or laboratory abnormality that, in&#xD;
             the opinion of the investigator, would jeopardize the safety of the patient or&#xD;
             potentially impact patient compliance or the safety/efficacy observations in the&#xD;
             study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Franciscan Health Michigan City</name>
      <address>
        <city>Michigan City</city>
        <state>Indiana</state>
        <zip>46360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dafer Al-Haddadin, MD</last_name>
      <phone>219-879-6531</phone>
      <email>dafer.al-haddadin@franciscanalliance.org</email>
    </contact>
    <contact_backup>
      <last_name>Kathy Kioussopoulos</last_name>
      <phone>317 528 8786</phone>
      <email>Kathleen.Kioussopoulos@franciscanalliance.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Ascension.Via Christi Research</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Margaret Hagan, MD</last_name>
      <phone>316-291-4774</phone>
      <email>dr.hagan@viachristi.org</email>
    </contact>
    <contact_backup>
      <last_name>Janie Krull</last_name>
      <phone>316-268-8015</phone>
      <email>janie.krull@ascension.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>South Jersey Infectious Disease</name>
      <address>
        <city>Somers Point</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Lucasti, DO</last_name>
      <phone>609-927-6662</phone>
      <email>infect123@aol.com</email>
    </contact>
    <contact_backup>
      <last_name>Kelly Freeman</last_name>
      <phone>609-927-6662</phone>
      <email>Kelly.Freeman@sjidtrials.net</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centro Gallego</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1094AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Cruz, MD</last_name>
      <phone>+54 9 11 3573 6301</phone>
      <email>imojen@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Mariana Calenda</last_name>
      <phone>(549) 113-1142</phone>
      <phone_ext>920</phone_ext>
      <email>calendm@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinica de los Virreyes</name>
      <address>
        <city>Buenos Aires</city>
        <state>Capital Federal</state>
        <zip>C1426AGU</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Hojman, MD</last_name>
      <phone>54 9 11 555235569</phone>
      <email>martin_hojman@hotmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Paula Hojman</last_name>
      <phone>54 9 11530632999</phone>
      <email>paulahojman@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital Rawson</name>
      <address>
        <city>Cordoba</city>
        <state>Cuidad De Cordoba</state>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorena Ravera, MD</last_name>
      <phone>54-9- 351-3114358</phone>
      <email>lorena.ravera@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>David Viviana</last_name>
      <phone>54 9 351 5511771</phone>
      <email>cic.hospitalrawson@gmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clínica Internacional S.A. - Sede Lima</name>
      <address>
        <city>Lima Cercado</city>
        <state>Lima</state>
        <zip>15001</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alfredo Guerreros, MD</last_name>
      <phone>511-998315497</phone>
      <email>aguerreros@cinternacional.com.pe</email>
    </contact>
    <contact_backup>
      <last_name>Cinthya Ballona Valdiva</last_name>
      <phone>+51 995146194</phone>
      <email>pierina6@hotmail.com</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hospital de Chancay</name>
      <address>
        <city>Chancay</city>
        <zip>15131</zip>
        <country>Peru</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oscar Carbajal Paulet, MD</last_name>
      <phone>(+51) 992 772 760</phone>
      <email>ocarbajalp@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Lisbeth Cahuas Villanueva</last_name>
      <phone>(+51) 964 397 935</phone>
      <email>lizitavillanueva@hotmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Peru</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 19, 2020</study_first_submitted>
  <study_first_submitted_qc>August 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 21, 2020</study_first_posted>
  <last_update_submitted>January 21, 2021</last_update_submitted>
  <last_update_submitted_qc>January 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Antroquinonol</keyword>
  <keyword>COVID 19</keyword>
  <keyword>pneumonia</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

